Life Healthcare will report a drop of up to 26% in headline earnings per share (HEPS) even as revenue grew and it saw increased patient stays in its hospitals and mental health clinics, and a rise in sales of its diagnostic drug used in the US for Alzheimer’s patients.

The group said HEPS would be 10%-26% lower as it faced rising costs including salaries, higher interest on debt, load-shedding and increased expenditure on IT. ..

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.